Eirini Kelaiditi1, Marco Canevelli1,2, Sandrine Andrieu1,3,4,5, Natalia Del Campo1, Maria E Soto1,3, Bruno Vellas1,3,4, Matteo Cesari1,3,4. 1. Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. 2. Memory Clinic, Department of Neurology and Psychiatry, "Sapienza" University, Rome, Italy. 3. Unité Mixte de Recherche 1027, Institut National de la Santé et de la Recherche Médicale, Toulouse, France. 4. Université de Toulouse III Paul Sabatier, Toulouse, France. 5. Department of Public Health, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Abstract
OBJECTIVES: To determine whether the Frailty Index (FI) was associated with short-term cognitive decline (according to changes in Mini Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores at 1-year follow-up) in individuals with Alzheimer's disease (AD). DESIGN: Prospective cohort study. SETTING: Impact of Cholinergic Treatment USe study. PARTICIPANTS: Individuals with mild-to-moderate AD (N = 973). MEASUREMENTS: Severity of dementia was assessed using the Clinical Dementia Rating (CDR). FI was calculated as the ratio of actual to potential deficits (deficits present divided by 30). Linear regression analyses were performed and stratified according to severity of dementia. RESULTS: A 1-unit (0.033 points) increase in FI corresponded to significant and clinically relevant cognitive decline, after adjustments for age, sex, and years of education (0.63-4.63 points on the MMSE, P = .01; 2.87-11.1 points on the ADAS-Cog, P = .001) after 1 year of follow-up. Differences in changes in MMSE and ADAS-Cog scores between nonfrail and frail individuals were 0.67 and 1.6 points, respectively. Although statistically significant, the clinical relevance of this finding remains to be further investigated. CONCLUSION: The FI may be a promising instrument for the assessment of the vulnerability of individuals with AD. Its implementation in clinical practice may support clinical decisions by identifying individuals at high risk of negative outcomes, specifically, short-term cognitive decline.
OBJECTIVES: To determine whether the Frailty Index (FI) was associated with short-term cognitive decline (according to changes in Mini Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores at 1-year follow-up) in individuals with Alzheimer's disease (AD). DESIGN: Prospective cohort study. SETTING: Impact of Cholinergic Treatment USe study. PARTICIPANTS: Individuals with mild-to-moderate AD (N = 973). MEASUREMENTS: Severity of dementia was assessed using the Clinical Dementia Rating (CDR). FI was calculated as the ratio of actual to potential deficits (deficits present divided by 30). Linear regression analyses were performed and stratified according to severity of dementia. RESULTS: A 1-unit (0.033 points) increase in FI corresponded to significant and clinically relevant cognitive decline, after adjustments for age, sex, and years of education (0.63-4.63 points on the MMSE, P = .01; 2.87-11.1 points on the ADAS-Cog, P = .001) after 1 year of follow-up. Differences in changes in MMSE and ADAS-Cog scores between nonfrail and frail individuals were 0.67 and 1.6 points, respectively. Although statistically significant, the clinical relevance of this finding remains to be further investigated. CONCLUSION: The FI may be a promising instrument for the assessment of the vulnerability of individuals with AD. Its implementation in clinical practice may support clinical decisions by identifying individuals at high risk of negative outcomes, specifically, short-term cognitive decline.
Authors: He Zhou; Catherine Park; Mohammad Shahbazi; Michele K York; Mark E Kunik; Aanand D Naik; Bijan Najafi Journal: Gerontology Date: 2021-05-10 Impact factor: 5.597
Authors: Marco Canevelli; Alessandro Trebbastoni; Federica Quarata; Fabrizia D'Antonio; Matteo Cesari; Carlo de Lena; Giuseppe Bruno Journal: Front Neurol Date: 2017-11-27 Impact factor: 4.003
Authors: Marco Canevelli; Ivan Arisi; Ilaria Bacigalupo; Andrea Arighi; Daniela Galimberti; Nicola Vanacore; Mara D'Onofrio; Matteo Cesari; Giuseppe Bruno Journal: Geroscience Date: 2020-11-19 Impact factor: 7.713
Authors: Alessandro Trebbastoni; Marco Canevelli; Fabrizia D'Antonio; Letizia Imbriano; Livia Podda; Lidia Rendace; Alessandra Campanelli; Valentina Celano; Giuseppe Bruno; Carlo de Lena Journal: Front Med (Lausanne) Date: 2017-10-23
Authors: Marco Canevelli; Matteo Cesari; Francesca Remiddi; Alessandro Trebbastoni; Federica Quarata; Carlo Vico; Carlo de Lena; Giuseppe Bruno Journal: Front Aging Neurosci Date: 2017-02-24 Impact factor: 5.750